J Korean Neurol Assoc.
2020 May;38(2):100-110. 10.17340/jkna.2020.2.3.
An Update On Migraine Treatment
- Affiliations
-
- 1Department of Neurology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
- 2Department of Neurology, Chung-Ang University Hospital, Chung-Ang University College of Medicine, Seoul, Korea
- 3Department of Neurology, Seoul Paik Hospital, Inje University College of Medicine, Seoul, Korea
- 4Department of Neurology, Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea
- KMID: 2501755
- DOI: http://doi.org/10.17340/jkna.2020.2.3
Abstract
- Globally, migraine is the third most common disease affecting 1.3 billion people worldwide and the second leading cause of disability. With the recent advances in new drugs and device technology for the treatment of migraine, the Korean Headache Society (KHS) and American Headache Society (AHS) released a new practice guideline on the treatment of migraine in 2019, respectively. They developed their consensus statement after reviewing existing guidelines and recent clinical trials and having discussions with stakeholders. The KHS guideline addresses best practice for preventing migraine with oral treatments including start and stopping strategies. The AHS statement dealt with newer treatments, such as onabotulinumtoxinA, and the recently approved calcitonin gene-related peptide targeting agents, and nonpharmacological treatments such as neuromodulation and biobehavioral therapy for both preventive and acute treatment. In this paper, we will review and summarize updated guideline for migraine treatment.
